ABT — Abbott Laboratories

Is ABT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Oversold As of November 17, 2026

Abbott Laboratories (ABT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $104.71. The rating moved from Neutral to Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Abbott presents a balanced growth-and-quality profile driven by leadership in glucose monitoring, broad diagnostics capabilities and established device franchises. The business generates steady free cash flow and benefits from defensive investor flows into large-cap healthcare, while ongoing product innovation and the company’s global commercial scale support continued market share gains and margin durability. Key near-term catalysts include continued CGM uptake, new product rollouts in procedures and stable diagnostic demand, offset by competitive pressure, potential reimbursement shifts and device-specific regulatory risk. Overall outlook points to modest upside over the coming weeks as fundamentals and defensive market positioning underpin performance.

Key factors

  • Diversified portfolio across medtech, diagnostics, nutrition and devices providing stable recurring revenue and margin resilience
  • Market leadership in continuous glucose monitoring (FreeStyle Libre) and broad diagnostics footprint driving durable revenue growth and higher-margin revenue streams
  • Strong cash flow generation and balance sheet flexibility supporting dividends, buybacks and selective M&A to sustain long-term growth
  • Exposure to procedural/device franchises (vascular, structural, electrophysiology) that can benefit from higher procedure volumes and OR investment tied to surgical robotics expansion
  • Defensive large-cap healthcare flows in the current market environment provide support to valuation and reduce short-term downside volatility
  • Operational scale and global commercial reach enable faster adoption of new products and price negotiation power with payors and distributors

Risks

  • Intense competition in diabetes care and CGM from incumbents (e.g., Dexcom, Medtronic) that could pressure share and pricing
  • Reimbursement and regulatory changes (including CMS program integrity efforts) that could alter payer economics and customer purchasing behavior, indirectly impacting demand
  • Product-specific regulatory actions, recalls or clinical setbacks in device franchises that could hit near-term revenue and margins
  • Macro/healthcare volume cyclicality or hospital capital reallocation (e.g., toward robotics) that could change elective procedure trends and equipment spending patterns
  • Supply chain disruptions and FX exposure given global manufacturing and sales footprint
  • Slower-than-expected adoption in newer markets or pricing pressure on diagnostic/consumable revenue streams

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ABT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.